Cargando…

Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis

BACKGROUND: Recently, direct oral anticoagulants (DOACs) have been included in guidelines for the treatment of cancer-associated thrombosis (CAT) to be extended to suitable cancer patients. The purpose of this study was to compare the cost-effectiveness of using DOACs and low molecular weight hepari...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wumaier, Kaidireyahan, Li, Wenqian, Chen, Naifei, Cui, Jiuwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479897/ https://www.ncbi.nlm.nih.gov/pubmed/34587969 http://dx.doi.org/10.1186/s12959-021-00319-1

Ejemplares similares

New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism
por: Wumaier, Kaidireyahan, et al.
Publicado: (2022)

Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin
por: Tucker, Madeline, et al.
Publicado: (2021)

Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma
por: Dubinski, Daniel, et al.
Publicado: (2021)

Feasibility of anticoagulation using low molecular-weight heparin during catheter-directed thrombolysis for lower extremity deep venous thrombosis
por: Li, Yonghui, et al.
Publicado: (2021)

Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials
por: Moik, Florian, et al.
Publicado: (2020)

Low-molecular weight heparin infusion as anticoagulation for haemodialysis
por: Wong, Steve Siu-Man, et al.
Publicado: (2016)

Low molecular weight heparin and direct oral anticoagulants influence tumour formation, growth, invasion and vascularisation by separate mechanisms
por: Featherby, Sophie, et al.
Publicado: (2019)

Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism
por: Recio-Boiles, Alejandro, et al.
Publicado: (2019)

A meta-analysis of bridging anticoagulation between low molecular weight heparin and heparin
por: Tao, Ende, et al.
Publicado: (2020)

Reversal of the anticoagulant and anti-hemostatic effect of low molecular weight heparin by direct prothrombin activation
por: Andrade, S.A., et al.
Publicado: (2012)

Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis
por: Rungjirajittranon, Tarinee, et al.
Publicado: (2022)

The anticoagulants rivaroxaban and low molecular weight heparin prevent PICC-related upper extremity venous thrombosis in cancer patients
por: Lv, Shoutian, et al.
Publicado: (2019)

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
por: Shute, Janis Kay
Publicado: (2023)

Recent Advances in Anticoagulant Treatment of Immune Thrombosis: A Focus on Direct Oral Anticoagulants in Heparin-Induced Thrombocytopenia and Anti-Phospholipid Syndrome
por: Carré, Julie, et al.
Publicado: (2021)

Measuring the anticoagulant effect of low molecular weight heparins in the critically ill
por: Crowther, Mark, et al.
Publicado: (2006)

Non-Anticoagulant Activities of Low Molecular Weight Heparins—A Review
por: Feng, Ke, et al.
Publicado: (2023)

Low molecular weight heparin versus unfractionated heparin in the management of cerebral venous thrombosis: A systematic review and meta-analysis
por: Qureshi, Anjum, et al.
Publicado: (2017)

Comparative Efficacy of Direct Oral Anticoagulants and Low-Molecular-Weight Heparin in Cancer-Associated Thromboembolism: A Systematic Review and Meta-Analysis
por: Patel, Tirath, et al.
Publicado: (2023)

Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials
por: Frere, Corinne, et al.
Publicado: (2022)

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015)

Patients’ Plasma Activity of Heparin, low-Molecular-Weight Heparin or no Anticoagulants on Urine Based DOAC Test Strips
por: Harenberg, Job, et al.
Publicado: (2022)

A direct comparison of prophylactic low-molecular-weight heparin versus unfractionated heparin in neurosurgery: A meta-analysis
por: Macki, Mohamed, et al.
Publicado: (2019)

Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis
por: Zakai, Neil A., et al.
Publicado: (2021)

Cancer‐associated thrombosis: Role of direct oral anticoagulants
por: Ikeda, Masataka, et al.
Publicado: (2018)

Regional citrate anticoagulation versus low molecular weight heparin anticoagulation for continuous venovenous hemofiltration in patients with severe hypercalcemia: a retrospective cohort study
por: Yu, Yan, et al.
Publicado: (2020)

Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants
por: Kumano, Osamu, et al.
Publicado: (2021)

Safety and Feasibility of Subcutaneous Low Molecular Weight Heparin for Cerebral Venous Sinus Thrombosis
por: Kim, Ji Seon, et al.
Publicado: (2005)

Low molecular weight heparin versus unfractioned heparin for anticoagulation during perioperative extracorporeal membrane oxygenation: A single center experience in 102 lung transplant patients
por: Gratz, Johannes, et al.
Publicado: (2020)

Prophylactic anticoagulation with low molecular weight heparin in COVID-19: cohort studies in Denmark and Sweden
por: Lund, Lars Christian, et al.
Publicado: (2022)

Promising Drug Fondaparinux for the Treatment of COVID-19: an In Silico Analysis of Low Molecular Weight Heparin, Direct Oral Anticoagulant, and Antiplatelet Drug Interactions with Host Protease Furin
por: Ertan-Bolelli, Tugba, et al.
Publicado: (2022)

P1669: DIRECT ORAL ANTICOAGULANTS VS LOW MOLECULAR WEIGHT HEPARIN IN THE MANAGEMENT OF PATIENTS WITH PRIMARY OR METASTATIC BRAIN TUMOURS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Yu, Wenhui, et al.
Publicado: (2023)

The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis
por: Al-Samkari, Hanny, et al.
Publicado: (2018)

Postoperative Ovarian Vein Thrombosis and Treatment with Direct Oral Anticoagulant
por: Shukr, Ghadear, et al.
Publicado: (2023)

Low Molecular Weight Heparin: A Practical Approach in Deep Venous Thrombosis in Palliative Care
por: Dutta, Samrat, et al.
Publicado: (2011)

Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study
por: Seaman, Siwan, et al.
Publicado: (2014)

Low Molecular Weight Heparin in Portal Vein Thrombosis of Cirrhotic Patients: Only Therapeutic Purposes?
por: Licinio, Raffaele, et al.
Publicado: (2014)

Efficacy of Low Molecular Weight Heparin in Preventing Perinatal Venous Thrombosis: A Meta-Analysis
por: Huang, Yan, et al.
Publicado: (2022)

Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients
por: Han, Ji Min, et al.
Publicado: (2023)

Effects of intensive insulin therapy combined with low molecular weight heparin anticoagulant therapy on severe pancreatitis
por: DU, JUN-DONG, et al.
Publicado: (2014)

Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials
por: Marcucci, Maura, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o4c78rsmrg5jfmjvf125vbt1ds